HIMS Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws by Hims & Hers Health, Inc. following a lawsuit filed by the Federal Trade Commission (FTC). The FTC accuses HIMS of sharing customers' medical information with third-party advertisers, causing HIMS's stock price to drop over 14%. The law firm is encouraging investors who experienced losses to contact them to discuss their legal rights.
Hims & Hers (NYSE: HIMS) policy chief sells shares under 10b5-1 plan
Deborah M. Autor, Chief Policy Officer and a director at Hims & Hers Health, Inc. (HIMS), sold 16,773 shares of Class A Common Stock at $27.85 per share on August 18, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2026. Following the sale, Ms. Autor directly holds 48,961 shares of the company's Class A Common Stock.
Hims & Hers Health (NYSE: HIMS) CEO Disposes Of 78,859 Shares In Routine Tax Withholding Event
Hims & Hers Health CEO Andrew Dudum disposed of 78,859 shares of Class A Common Stock, valued at approximately $2.2 million, to cover mandatory tax withholding obligations related to RSU vesting. This non-discretionary transaction reduced his direct holdings by 7% but his total equity position remains substantial at 9.7 million shares. The event follows the company's Q2 earnings report and a recent FTC lawsuit, with financial results showing strong revenue growth but declining gross margins due to a shift towards branded weight loss drugs.
HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission (FTC) filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following news of the FTC lawsuit, HIMS's stock price dropped over 14%. The firm is encouraging investors who experienced financial losses to contact them to discuss their legal rights.
Hims & Hers Health | 144: Notice of proposed sale of securities pursuant to Rule 144
This document indicates a proposed sale of securities for Hims & Hers Health, filed pursuant to Rule 144. Rule 144 allows for the resale of restricted and control securities without registration if certain conditions are met.
HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential federal securities law violations after the Federal Trade Commission (FTC) filed a lawsuit against HIMS. The FTC accuses HIMS of sharing customers' medical information with third-party advertisers, leading to a more than 14% drop in the company's stock price. Investors who experienced losses are encouraged to contact the firm to discuss their legal rights.
Hims & Hers Director Kare Schultz Granted 8,223 RSUs on August 12, 2026
Hims & Hers Health, Inc. (NASDAQ:HIMS) Director Kare Schultz was granted 8,223 Restricted Stock Units (RSUs) on August 12, 2026, as disclosed in a Form 4 filed with the SEC on August 14, 2026. These RSUs were granted at no cost and will vest fully on the first quarterly vesting date after either the next annual stockholder meeting or the first anniversary of the grant date, subject to Schultz's continuous service. Following this transaction, Schultz directly holds 8,223 derivative securities.
Kaplan Fox is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. This investigation follows a lawsuit filed by the FTC and California/Utah authorities alleging that Hims & Hers failed to clearly disclose prescription charges, made it difficult to cancel subscriptions, and misled consumers about health data privacy by sharing information with third parties. Following this news, Hims & Hers stock dropped by 14.73%.
FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions
The Federal Trade Commission, alongside the State of California and Utah Division of Consumer Protection, has filed a lawsuit against Hims & Hers Health Inc. The lawsuit alleges that Hims & Hers misled consumers by charging them for prescription medication subscriptions they never agreed to purchase and by deceiving them about billing practices. Furthermore, the complaint claims Hims & Hers violated data privacy promises by sharing patient health information with advertisers like Meta and Snap.
Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims
A new class action lawsuit has been filed against Hims & Hers Health Inc., alleging that the telehealth company secretly shared sensitive patient health data and identifying details with advertising and analytics firms like Meta, Google, and Snap without consent. The lawsuit claims that tracking software embedded in Hims & Hers' websites and apps transmitted medical intake answers and personal information, contradicting the company's privacy policies. This legal action follows a separate enforcement action by the FTC and state divisions regarding similar allegations of data disclosure and advertising audience building.
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS)
Berger Montague PC has initiated an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) for potential breaches of fiduciary duties. The investigation focuses on allegations that the company improperly shared user health data with advertisers, engaged in deceptive billing, and made subscription cancellations difficult. Shareholders are invited to contact the firm for more information regarding this inquiry.
FTC Continues Investigation into Hims & Hers Health, Inc.
Lowey Dannenberg, P.C. has filed a class action complaint against Hims & Hers Health, Inc., alleging the company misrepresented privacy and shared sensitive health information without consent. This complaint follows a civil enforcement action by the FTC and other state bodies against Hims & Hers, accusing them of privacy violations, deceptive billing, and difficult subscription cancellation practices. The class action seeks damages, restitution, and injunctive relief, with Lowey Dannenberg emphasizing its commitment to protecting private health data.
The Technical Signals Behind (HIMS) That Institutions Follow
The article analyzes Hims & Hers Health Inc. (HIMS) using AI models to identify technical signals and institutional trading strategies. It highlights a near-term strong sentiment for HIMS that could challenge persistent mid and long-term weakness, noting resistance testing and a significant risk-reward short setup. The piece provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.
Hims Earnings: Subscriber Growth Impressive but Not Enough to Overlook Continued Margin Slip
Hims & Hers reported a 38% increase in revenue for the second quarter, surpassing management's expectations. However, adjusted EBITDA declined by 27%, leading to a post-market share drop. The impressive subscriber growth was overshadowed by the continued slip in margins.
Hers Health, Inc. Reports Second Quarter 2026 Financial Results
Hims & Hers Health, Inc. announced strong financial results for Q2 2026, with revenue up 38% year-over-year to $753 million and subscribers growing to nearly 2.9 million. The company raised its full-year 2026 revenue guidance to $3.1 billion to $3.3 billion and updated its Adjusted EBITDA guidance to $275 million to $325 million, driven by domestic growth acceleration and international expansion, including the Eucalyptus acquisition. The company attributes its success to a doctor-led AI clinical engine and a focus on accessible, high-quality care.
HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Hims & Hers Health, Inc. (NYSE:HIMS) following a lawsuit filed by the FTC and California alleging violations of federal securities laws and unlawful business practices. The lawsuit claims Hims & Hers failed to disclose prescription charges, made it difficult to cancel subscriptions, and shared consumer health information with third parties. Following this news, Hims & Hers stock fell 14.73%.
Kaplan Fox Notifies Hims & Hers Health, Inc. (HIMS) Investors of a Securities Investigation into the Company
Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Hims & Hers Health, Inc. (HIMS) following a lawsuit filed by the FTC, California, and Utah alleging that the company failed to disclose prescription charges clearly, made it difficult to cancel subscriptions, and misled consumers about privacy by sharing health information with third parties. This news led to a 14.73% drop in Hims & Hers' stock price on July 29, 2026. The law firm is seeking to connect with investors who have suffered losses and have information relevant to the investigation.
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of an Ongoing Investigation Into Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Hims & Hers Health, Inc. following a lawsuit filed by the FTC and California/Utah consumer protection agencies. The lawsuit alleges that Hims & Hers failed to clearly disclose prescription charges, made it difficult to cancel subscriptions, and misled consumers about the privacy of their health information, reportedly sharing it with third parties like Meta and Snap. This news caused Hims & Hers stock to drop by 14.73% on July 29, 2026.
HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney
Kirby McInerney LLP has announced an investigation into potential securities fraud against Hims & Hers Health, Inc. following a lawsuit filed by the Federal Trade Commission (FTC). The FTC accused Hims of sharing customers’ medical information with third-party advertisers, specifically Meta Platforms, leading to a 14.73% drop in Hims' stock price. The law firm is encouraging investors who purchased Hims securities to contact them regarding this investigation.
HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney
Kirby McInerney LLP is investigating potential securities fraud claims against Hims & Hers Health, Inc. (NYSE: HIMS) following a lawsuit filed by the Federal Trade Commission (FTC). The FTC accuses Hims of sharing customers' medical information with third-party advertisers, leading to a significant drop in Hims's stock price. The law firm is encouraging investors affected by this news to contact them regarding their rights.
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Hims & Hers Health, Inc. (HIMS) after the Federal Trade Commission (FTC) filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news on July 29, 2026, Hims' shares declined by 14.73%. The law firm is urging investors who lost money to contact them to potentially pursue claims.
Weekly Recap: Hims & Hers data-sharing suit and FDA panel backs peptides
Hims & Hers (HIMS) is facing lawsuits from the FTC, Los Angeles County, and Utah over alleged data-sharing with Meta and Snap, as well as deceptive billing practices. Simultaneously, the company is exploring opportunities in the peptides market after an FDA advisory panel recommended adding several peptides to the 503A list. This development comes despite the peptides remaining unapproved and their market size being uncertain.
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news, HIMS's stock price dropped over 14%. The firm is encouraging investors who experienced losses to contact them to discuss their legal rights.
Securities Fraud Class Action Filed Against Hims & Hers Health, I
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Hims & Hers Health, Inc. (HIMS) on behalf of investors who suffered losses between April 29, 2025, and June 23, 2025. The lawsuit alleges that the company engaged in deceptive promotion of "knockoff" versions of Wegovy®, risking the termination of its collaboration with Novo Nordisk, and that its positive business statements were misleading. Investors are encouraged to seek information regarding potential recovery.
Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS)
A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS), alleging securities fraud for making false statements regarding the deceptive promotion and sale of "knockoff" versions of Wegovy®. Shareholders who suffered losses between April 29, 2025, and June 23, 2025, are encouraged to contact Levi & Korsinsky LLP by August 25, 2025, to learn about their rights to recover losses. The lawsuit claims that these actions put patient safety at risk and could lead to the termination of the company's collaboration with Novo Nordisk.
Hims & Hers Health stock may move 14% on Aug. 10 earnings
Hims & Hers Health Inc. Class A shares are projected to move 14% on August 10 when the company reports earnings, according to options data. Historically, the stock's actual movement has often differed from options-implied moves, sometimes falling significantly even when options suggested a strong move. This article was generated with AI support and reviewed by an editor.
Precision Trading with Hims & Hers Health Inc. Class A (HIMS) Risk Zones
The article provides a precise trading analysis for Hims & Hers Health Inc. Class A (HIMS), identifying a weak sentiment across all horizons that supports a short bias. It details an exceptional 126.1:1 risk-reward short setup with significant downside targets. Three distinct AI-generated trading strategies—position, momentum breakout, and risk hedging—are outlined to suit various risk profiles and holding periods.
Precision Trading with Hims & Hers Health Inc. Class A (HIMS) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Hims & Hers Health Inc. Class A (HIMS), highlighting a weak sentiment across all time horizons supporting a short bias. It outlines an exceptional 126.1:1 risk-reward short setup and offers three distinct AI-generated trading strategies for different risk profiles. The analysis includes entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies.
Hims & Hers Tokenized Stock price today, HIMSx to USD chart, marketcap and volume
This article provides current information on Hims & Hers Tokenized Stock (HIMSx), including its price, market cap, trading volume, and a detailed chart. HIMSx is a blockchain-based tokenized representation of Hims & Hers Health, Inc. Class A common stock, issued through Backed Finance's xStocks framework, offering eligible investors on-chain exposure to the stock's economic performance. The token launched in 2025 and is backed by underlying shares held by a qualified custodian, integrating traditional financial assets with blockchain technology.
BlackRock (NYSE: BLK) discloses 11.9% beneficial stake in Hims & Hers (HIMS)
BlackRock, Inc. has disclosed a significant passive ownership stake of 11.9% in Hims & Hers Health Inc. Class A stock, according to an SEC Schedule 13G/A filing. This report details that BlackRock beneficially owns 26,496,218 shares, over which it holds sole dispositive power and nearly full sole voting power. The filing also clarifies that no single underlying client holds more than five percent of Hims & Hers Health Inc.'s outstanding common shares.
Hims & Hers Health, Inc. (HIMS) Stock Price, News, Quote & History
Hims & Hers Health, Inc. (HIMS) stock is currently trading at $29.32, down 3.04% for the day. The article provides a comprehensive overview of the company, including its stock performance, key financial metrics, recent news, analyst recommendations, and comparisons to similar companies. Hims & Hers operates a consumer-first health and wellness platform offering prescription and non-prescription products and services across various health categories.
Hims & Hers Health, Inc. Class A Revenue Breakdown – HAM:82W
This article provides a revenue breakdown for Hims & Hers Health, Inc. Class A (HAM:82W), highlighting its financial performance from the Hamburg Stock Exchange. The company generated 2.00 billion EUR last year, with the online segment contributing the most at 1.97 billion EUR. The United States was the primary regional contributor, accounting for 1.88 billion EUR of the revenue.
Hims & Hers Health: Favorable Decision on Peptides Lifts Investor Appetite but Uncertainty Very High
Hims & Hers Health saw its stock rise after the FDA advisory committee decided to list BPC-157, a popular peptide, in a way that could allow compounding pharmacies to mass-produce it. This regulatory decision has boosted investor interest in Hims & Hers, despite high uncertainty surrounding the long-term implications. The article highlights the immediate positive reaction from the market.
Technical Reactions to HIMS Trends in Macro Strategies
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS), revealing strong near and mid-term sentiment, but a weak long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report highlights potential upside due to the absence of resistance levels above the current price.
Technical Reactions to HIMS Trends in Macro Strategies
This article provides a technical analysis of Hims & Hers Health Inc. (NASDAQ: HIMS) based on AI models from Stock Traders Daily. It highlights strong near and mid-term sentiment, a weak long-term outlook, and compelling upside potential due to a lack of resistance levels. The analysis includes distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis.
Technical Reactions to HIMS Trends in Macro Strategies
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS) using AI models to identify potential trading strategies. It highlights a strong near and mid-term positive sentiment, but a weak long-term outlook, and provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Technical Reactions to HIMS Trends in Macro Strategies
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS) using AI models to provide technical reactions and trading strategies. It highlights a strong near and mid-term sentiment but a weak long-term outlook, identifying potential upside with no resistance levels above the current price. The report details three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Hims & Hers CFO Okupe sells $261k in stock
Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, sold Class A Common Stock worth approximately $261,351 after exercising stock options. This transaction was part of a pre-arranged trading plan, and Okupe now directly holds 284,321 shares. The company has also seen positive analyst updates, with several firms raising their price targets due to Hims & Hers' strategic moves in weight loss drugs and partnership with Novo Nordisk.
Hims & Hers (NYSE: HIMS) CFO exercises options and sells 7,163 shares under 10b5-1 plan
Hims & Hers Health, Inc. CFO Oluyemi Okupe exercised stock options for 7,163 shares at $5.01 per share and subsequently sold the same number of shares at an average price of $36.4863 per share. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, Okupe directly holds 284,321 shares and indirectly holds 7,853 shares, with 102,361 stock options remaining.
Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS) - Recover Losses - Contact Levi & Korsinsky Before August 25, 2025
A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) alleging securities fraud between April 29, 2025, and June 23, 2025. The lawsuit claims Hims engaged in deceptive promotion of "knockoff" versions of Wegovy, risking termination of its collaboration with Novo Nordisk. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP by August 25, 2025, to learn about their rights.
Hims & Hers Health, Inc. Class A Trade Ideas — SIX:HIMS.USD
This article compiles various trade ideas and analyses for Hims & Hers Health, Inc. (HIMS) stock, covering different perspectives from bullish long-term outlooks to cautious short-term setups. Key themes include the company's strong June performance, expansion into new markets and treatments like peptides and GLP-1s, and strategic partnerships, alongside discussions on insider selling, potential dilution from convertible notes, and the challenges of achieving sustained profitability.
HIMS Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. (HIMS) Shareholders of Securities Fraud Class Action Lawsuit Deadline
Kessler Topaz Meltzer & Check, LLP has issued a reminder to shareholders of Hims & Hers Health, Inc. (HIMS) about an ongoing securities fraud class action lawsuit. Investors who purchased HIMS securities between April 29, 2025, and June 23, 2025, are affected, and the lead plaintiff deadline is August 25, 2025. The lawsuit alleges that Hims & Hers misrepresented its business by deceptively promoting and selling "knockoff versions of Wegovy," leading to a substantial risk of terminated collaboration with Novo Nordisk.
Lost Money on Hims & Hers Health, Inc. (HIMS)? Join Class Action Before August 25, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) for alleged securities fraud between April 29, 2025, and June 23, 2025. The lawsuit claims that Hims engaged in deceptive promotion of "knockoff" versions of Wegovy®, posing risks to patient safety and potentially jeopardizing its collaboration with Novo Nordisk. Shareholders who incurred losses during this period are encouraged to contact Levi & Korsinsky to learn about their rights to participate in the recovery effort before August 25, 2025.
Trading the Move, Not the Narrative: (HIMS) Edition
This article provides an AI-generated analysis for Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting weak near-term sentiment but mid-term strength within a long-term weak bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
Hims & Hers Health, Inc. Class A Actuals & Estimates (NYSE:HIMS)
This article provides an overview of Hims & Hers Health, Inc. (NYSE:HIMS) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The content also includes frequently asked questions about investing in HIMS stock.
Price to book forward of Hims & Hers Health, Inc. Class A – XETR:82W
This article provides access to the "Price to book forward" financial metric for Hims & Hers Health, Inc. Class A (XETR:82W) on TradingView. It indicates that the market was closed at the time of publication and there were no trades. The content primarily directs users to various sections of the TradingView platform for financial data, community, and other products related to this stock.
Hims & Hers CMO Patrick Carroll sells $830,410 in stock
Patrick Carroll, CMO of Hims & Hers Health, Inc., sold 23,726 shares of company stock for $830,410 on June 18, 2026. This transaction reduced his direct holdings to 181,861 shares of Class A Common Stock. The sale follows other company developments, including a raised price target from Barclays and the appointment of a new Chief Medical Officer, Dr. Anant Vinjamoori, after an annual meeting where nine directors were elected.
Hims & Hers CMO Patrick Carroll sells $830,410 in stock
Patrick Harrison Carroll, CMO of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 23,726 shares of company stock for $830,410 at $35.0 per share on June 18, 2026. After this transaction, he directly holds 181,861 shares. This sale follows other recent company updates, including an increased price target from Barclays and the appointment of a new Chief Medical Officer, Dr. Anant Vinjamoori.
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity
Hims & Hers Health, Inc. CFO Oluyemi Okupe reported stock option exercises and sales of common shares under a pre-arranged Rule 10b5-1 trading plan. Okupe exercised 6,376 shares of Class A common stock at $5.01 per share and sold 18,197 shares at an average price of $34.0285 per share. Following these transactions, Okupe holds 284,321 direct shares and 7,853 indirect shares of Class A common stock.
Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares By Investing.com
Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, sold 18,197 shares of Class A Common Stock for $619,216 on June 22, 2026, after exercising stock options. The sale was executed under a Rule 10b5-1 trading plan. This transaction follows other company developments, including a raised price target from Barclays and an upcoming regulatory meeting regarding compounded peptides.
